Soft Tissue Sarcoma Education
Soft tissue sarcoma encompasses over 70 histological subtypes with distinct treatment approaches, and the first TCR-T cell therapy approval has opened a new chapter in sarcoma treatment. Knowledge Med sessions help physicians navigate subtype-specific management through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing soft tissue sarcoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Applying histology-specific treatment approaches across diverse sarcoma subtypes
- Selecting systemic therapy (doxorubicin, gemcitabine-docetaxel, trabectedin) based on subtype
- Identifying candidates for TCR-T cell therapy (afamitresgene autoleucel) in synovial sarcoma
- Integrating targeted agents for GIST, DFSP, and other molecularly defined subtypes
What Sessions Cover
Knowledge Med Soft Tissue Sarcoma sessions use interactive case simulations to address these topics and more.
- Histology-driven first-line treatment selection in advanced soft tissue sarcoma
- TCR-T cell therapy in synovial sarcoma: eligibility, logistics, and monitoring
- Targeted therapy for molecularly defined sarcoma subtypes
- Emerging immunotherapy approaches and clinical trial landscape in sarcoma
Interactive Soft Tissue Sarcoma Sessions
Case Simulations
Work through realistic soft tissue sarcoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Soft Tissue Sarcoma clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Soft Tissue Sarcoma Session
Third-party, non-promotional soft tissue sarcoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session